Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone with or without docosahexaenoic acid for subjective memory complaints with elevated brain amyloid
ACTRN12618000761268Phase 2Recruiting
- Sponsor
- Australian Alzheimer's Research Foundation
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of testosterone undecanoate and docosahexaenoic acid in aging-related decline, confusion and Alzheimer's disease (AD) (3 arms), sponsored by Australian Alzheimer's Research Foundation. Started Apr 2018; status: recruiting.
02
Drugs
testosterone undecanoatedocosahexaenoic acid
03
Conditions
aging-related declineconfusionAlzheimer's disease (AD)
Beyond the preview
Go deeper on ACTRN12618000761268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000761268.